Comparative evaluation of the levels of fibroblast growth factor-2 prepared from Advanced Platelet Rich Fibrin (A-PRF) in diabetic patients and healthy subjects in Saudi Arabia

Background: Recently, attempts have been made to alter the centrifugation time in platelet-rich fibrin (PRF) preparation protocols; it was believed that lowspeed centrifugation (LSCC) improves growth factor release via PRF scaffolds. Diabetes mellitus is a serious, chronic human metabolic disease that has a tremendous impact on patients, families, and society. The objective of this study was to compare the levels of fibroblast growth factor-2 in advanced platelet-rich fibrin (A-PRF) in diabetic patients and those of healthy subjects from Saudi Arabia. Methods: Blood samples were obtained from diabetic patients at Riyadh Elm University, Saudi Arabia. Eligibility for the participants to be involved in this study was assessed. Samples were obtained from 38 volunteers, 30 patients with type1 and type 2 diabetes mellitus (test group), and eight non-diabetic volunteers (control group). Blood was extracted using 10 mL syringes and then processed using advanced plateletrich fibrin (A-PRF) centrifugation. A total of 10 milliliters of complete blood without anticoagulant was centrifuged at 1300 rpm (similar to 200 x g) for 14 min at 21-30 degrees C. Results: Measurements done at four different times (Days 1, 7, 14, and Day 28) revealed that the amount of FGF-2 released from A-PRF was significantly lesser among diabetes mellitus patients than in healthy volunteers. Conclusions: Compared to the non-diabetic individuals, a decrease in the FGF-2 level released from APRF in diabetic patients was observed.